Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
NeuroPace, Inc. Market Cap
Based on ratings from 0 stock analysts, the NeuroPace, Inc. stock price is expected to increase by 114.38% in 12 months. This is calculated by using the average 12-month stock price forecast for NeuroPace, Inc.. The lowest target is $8 and the highest is $20. Please note analyst price targets are not guaranteed and could be missed completely.
NeuroPace, Inc. has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that NeuroPace, Inc. will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of NPCE.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Vik Chopra Wells Fargo | Overweight | $15 | Maintains | Aug 14, 2024 |
| Ross Osborn Cantor Fitzgerald | Overweight | $18 | Reiterates | Aug 14, 2024 |
| Drew Ranieri Morgan Stanley | Equal-Weight | $8 | Maintains | Jul 15, 2024 |
| Ross Osborn Cantor Fitzgerald | Overweight | $18 | Reiterates | May 9, 2024 |
| Lawrence Biegelsen Wells Fargo | Overweight | $20 | Upgrade | Mar 14, 2024 |
| Robbie Marcus JP Morgan | Overweight | $17 | Maintains | Mar 12, 2024 |
| Ross Osborn Cantor Fitzgerald | Overweight | $18 | Maintains | Mar 6, 2024 |
| Drew Ranieri Morgan Stanley | Equal-Weight | $13 | Maintains | Mar 6, 2024 |
| Lawrence Biegelsen Wells Fargo | Equal-Weight | $16 | Maintains | Feb 22, 2024 |
| Mike Kratky Leerink Partners | Outperform | $22 | Initiates | Jan 30, 2024 |
| Frank Takkinen Lake Street | Buy | $12 | Reiterates | Dec 27, 2023 |
| Drew Ranieri Morgan Stanley | Equal-Weight | $9 | Maintains | Dec 4, 2023 |
| Drew Ranieri Morgan Stanley | Equal-Weight | $8 | Maintains | Nov 14, 2023 |
| Ross Osborn Cantor Fitzgerald | Overweight | $11 | Initiates | Nov 10, 2023 |
| Robbie Marcus JP Morgan | Overweight | $9 | Maintains | Nov 7, 2023 |
| Lawrence Biegelsen Wells Fargo | Equal-Weight | $9 | Maintains | Oct 4, 2023 |
| Drew Ranieri Morgan Stanley | Equal-Weight | $6 | Upgrade | Aug 24, 2023 |
| Drew Ranieri Morgan Stanley | Underweight | $5 | Maintains | May 5, 2023 |
| Drew Ranieri Morgan Stanley | Underweight | $4.5 | Maintains | Mar 3, 2023 |
| Frank Takkinen Lake Street | Buy | $10 | Initiates | Feb 22, 2023 |
When did it IPO
2021
Staff Count
179
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Joel D. Becker
Market Cap
$225.1M
In 2023, NPCE generated $65.4M in revenue, which was a increase of 43.72% from the previous year. This can be seen as a signal that NPCE's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
